Compass Therapeutics, Inc. — Director's Dealing 2026

Jan 5, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2026-01-02

Reporting Person: Prasad Arjun (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-02	STOCK OPTION (RIGHT TO BUY)	$5.17	A	1000000	Acquired	2036-01-02	COMMON STOCK (1000000)	Direct

Footnotes

F1: The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).

F2: The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.